Close
Novotech

Clinical Trials

LSK Global PS Adopts Veeva Vault Clinical Applications to Streamline Global Trial Processes

Veeva Systems announced that LSK Global Pharma Services Co. Ltd, a leading Korean contract research organization (CRO), has adopted Veeva Vault eTMF, Veeva Vault CTMS, and Veeva SiteVault Free. With Veeva Vault Clinical applications, LSK Global PS can streamline...

Regeneron Announces Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma

Regeneron Pharmaceuticals, Inc. announced detailed results from a Phase 2 proof-of-concept trial evaluating the investigational antibody cocktail REGN1908-1909 in cat-allergic patients with mild asthma. The trial met the primary endpoint of preventing early asthma reactions (EAR, defined as a...

The Impact of COVID-19 on Rare Disease Clinical Trials

Barriers and triumphs of an underserved patient group. It is undeniable that clinical trials for rare diseases are more challenging to design and execute. Unlike trials with more frequently occurring diseases, rare disease trials have a smaller number of eligible...

AiCure, OncoBay Clinical Partner to Improve Patient Care, Optimize Drug Development

AiCure and OncoBay Clinical announced a partnership to provide oncology sponsors with scalable, AI-powered insights to improve patient care and optimize drug development. A subsidiary of the Moffitt Cancer Center, OncoBay will make AiCure's proprietary AI platform available for...

Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico

Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced the complete enrollment of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety and immunogenicity of the company’s...

Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate

Sanofi and GSK announced the initiation of a new Phase 2 study with 720 volunteers aged 18 and over to select the most appropriate antigen dosage for Phase 3 evaluation of their adjuvanted recombinant protein COVID-19 vaccine candidate. “Over the...

Parexel and NeoGenomics announce partnership to improve clinical trials

Parexel, a leading provider of solutions to accelerate the development and delivery of innovative therapies to improve world health, from clinical through commercialization, and NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services and global oncology contract research...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »